Services for Life Sciences CFOs

Unlock insights. Activate growth.
Introducing CRA Life Sciences Consulting

For more than 25 years, life science companies around the globe have turned to CRA's life sciences consultants when they need clarity and solutions to the industry’s most complex issues. Clients value our deep industry knowledge, rigorous analytic techniques, and decades of hands-on experience spanning thousands of successful engagements.

A longstanding reputation

200+
consultants
A dedicated team of life sciences consultants
25+
years
Decades of hands-on life sciences experience
Top 30
pharmaceutical companies
Experience with all of the top 30 global pharmaceutical companies
95%
repeat clients
Repeat business from 95% of our clients

Comprehensive strategic expertise

We partner with clients to address strategic challenges at the corporate, portfolio, and product level.

 
Corporate
Portfolio
Asset
 
 
 
 
Drive company
growth
Shape portfolio
strategy
Prioritize investment decisions
 
 
 
 
Improve R&D performance
Focus development programs
Ensure robust
evidence generation
 
 
 
 
Adapt the business model
Optimize portfolio performance
Maximize launch
impact
 
 
 
 
Demonstrate value to wider stakeholders
Drive returns across
the portfolio
Achieve pricing and market access goals

Focused insights

Your challenges are at the heart of our strategic focus.

Corporate
  • How can we optimize growth – geographies, partnerships, products, business models?

  • How can we optimize R&D performance?

  • How do we evolve the business model to account for personalised healthcare & comprehensive services for patients

  • How can we enhance innovation through the emergence of diagnostics, patient monitoring, and digital health solutions

  • How can we best communicate value to external and internal stakeholders?

Portfolio
  • What is the optimal portfolio mix?

  • What portfolio expansion/divestment opportunities exist?

  • How can we optimize portfolio performance?

  • How do we optimize R&D investment across the portfolio?

  • How should we use generics, biosimilars, and OTC products?

  • How can we best communicate portfolio value to customers?

Asset
  • How do we maximize launch for our new brand (positioning, distribution, pricing, resource allocation, etc.)?

  • How do we achieve our global and local pricing and market access goals while optimizing asset value throughout the lifecycle?

  • How do we minimize competitive threats – new launches, LOE, biosimilars?

  • How can we turn around underperforming brands?

  • How do we optimize strategy over the product lifecycle?

Sample engagements

  • A client retained CRA to help them identify and prioritize opportunities for cancer vaccines across various solid tumors, in order to support their strategic alignment and future investment decisions. Recommendations resulted in a strategic shift within the organization and plans to eventually initiate early clinical trials from the prioritized opportunities.

  • A client wanted to evaluate partnering with an eHealth-related device to increase use of their product. CRA advised them to avoid the partnership, recommended partnerships with similar health technologies, and identified other actions that would increase use of the product.

  • A client turned to CRA when it wanted to inform its commercial investment decisions with pricing and access trends in oncology and the economics of tertiary care centers. CRA proposed a framework for assessing investments and recommendations for refining forecast estimates, which the client adopted.

<    >

Contacts

Elizabeth Rountree
Vice President
San Francisco, CA
+1 415-490-2730
erountree@crai.com

Erika Sloan
Principal
San Francisco
+1-415-490-2728
esloan@crai.com